Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma

This study examined the association of progression-free survival at 6 months with overall survival in the context of second-line therapy of advanced urothelial carcinoma in pooled patient-level data from 10 phase II trials and then externally validated in a large phase III trial. Progression-free su...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Agarwal, Neeraj, Bellmunt, Joaquim, Maughan, Benjamin L., Boucher, Kenneth M., Choueiri, Toni K., Qu, Angela Q., Vogelzang, Nicholas J., Fougeray, Ronan, Niegisch, Guenter, Albers, Peter, Wong, Yu-Ning, Ko, Yoo-Joung, Sridhar, Srikala S., Tantravahi, Srinivas K., Galsky, Matthew D., Petrylak, Daniel P., Vaishampayan, Ulka N., Mehta, Amitkumar N., Beer, Tomasz M., Sternberg, Cora. N., Rosenberg, Jonathan E., Sonpavde, Guru
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4142680/
https://ncbi.nlm.nih.gov/pubmed/24220220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2013.09.002
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares